Palivizumab vs Motavizumab: Number of Participants Reporting Any Adverse Events (AEs)
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
Measures 6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note | Source |
|---|---|---|---|---|---|---|
| Risk in group 1 | 0.86 | 0.848 | 0.872 | wilson | ClinicalTrials.gov | |
| Risk in group 2 | 0.856 | 0.844 | 0.868 | wilson | ClinicalTrials.gov | |
| Risk difference, group 1 minus group 2 | 0.00381 | -0.013 | 0.0206 | newcombe hybrid score | ClinicalTrials.gov | |
| Risk ratio, group 1 over group 2 | 1 | 0.985 | 1.02 | log | ClinicalTrials.gov | |
| Odds ratio, group 1 over group 2 | 1.03 | 0.899 | 1.18 | log | ClinicalTrials.gov | |
| Number needed to treat, for one more participant with the outcome on Palivizumab than on Motavizumab | 263 | from the risk difference interval | the interval includes no difference | ClinicalTrials.gov |
Groups 2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code | Source |
|---|---|---|---|---|---|---|
| Group 1 | Palivizumab | Palivizumab, 15 mg/kg administered intramuscularly for 5 monthly doses | 2,837 | 3,298 | OG000 | ClinicalTrials.gov |
| Group 2 | Motavizumab | Motavizumab, 15 mg/kg administered intramuscularly for 5 monthly doses | 2,839 | 3,315 | OG001 | ClinicalTrials.gov |
Outcome 5
| Field | Value | Source |
|---|---|---|
| Type | PRIMARY | ClinicalTrials.gov |
| Title | Number of Participants Reporting Any Adverse Events (AEs) | ClinicalTrials.gov |
| Description | Number of participants reporting one or more AEs | ClinicalTrials.gov |
| Time frame | Days 0 - 150 | ClinicalTrials.gov |
| Population | The Safety Population included all patients who received any study drug and had any safety follow-up. | ClinicalTrials.gov |
Trial 8
| Field | Value | Source |
|---|---|---|
| Title | Study of MEDI-524 (Motavizumab) for the Prophylaxis of Serious Respiratory Syncytial Virus (RSV) Disease in High-Risk Children | ClinicalTrials.gov |
| NCT number | NCT00129766 | ClinicalTrials.gov |
| Phases | PHASE3 | ClinicalTrials.gov |
| Conditions | Respiratory Syncytial Virus Infections | ClinicalTrials.gov |
| Interventions | motavizumab (MEDI-524), palivizumab | ClinicalTrials.gov |
| Lead sponsor | MedImmune LLC | ClinicalTrials.gov |
| Results first posted | 2013-08-28 | ClinicalTrials.gov |
| Results on ClinicalTrials.gov | https://clinicaltrials.gov/study/NCT00129766?tab=results | ClinicalTrials.gov |
Source 4
| Field | Value | Source |
|---|---|---|
| Release | trial-comparisons-2026-03-23-0.1.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57 | ClinicalTrials.gov |
| AACT copy | 2026-03-23 | ClinicalTrials.gov |
| Tables read | outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet | ClinicalTrials.gov |
Release trial-comparisons-2026-03-23-0.1.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.